INVESTMENTS

6 Months Ended

Jun. 30, 2025

Equity Method Investments and Joint Ventures [Abstract]

We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.

We account for investments in entities in which we have the ability to exercise significant influence under the equity method of accounting if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $97.9 million and $49.8 million as of June 30, 2025 and December 31, 2024, respectively, and is reflected in other assets within our condensed consolidated balance sheets.

During the three-month period ended March 31, 2025, a third-party acquired a majority of the membership interests of a newly formed entity which included one of our equity method investments, Medalogix, as well as a healthcare referral and workflow management company. We rolled 100% of our ownership interest in Medalogix into the newly formed entity, and in connection with the transaction, we recognized a $48.1 million gain based on the fair value of our equity in Medalogix upon executing the transaction, which is reflected in gain on equity method investment within our condensed consolidated income statement. We will continue to account for our investment in the new combined entity under the equity method of accounting in accordance with ASC 323, Investments - Equity Method and Joint Ventures.

We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. The book value of investments that we account for under the cost method of accounting was $19.1 million and $20.0 million as of June 30, 2025 and December 31, 2024, respectively, and is reflected in other assets within our condensed consolidated balance sheets. During the three-month period ended June 30, 2025, we determined the book value of one of our cost method investments exceeded its fair value. As a result, we recorded a non-cash impairment charge of $0.9 million, which is reflected in impairment within general and administrative expenses in our condensed consolidated income statement.

Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. We have management agreements in place whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding.

As of June 30, 2025, we are consolidating all of our joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We are in the process of winding down the operations of one of our consolidated joint ventures. As a result, we recorded an adjustment to the carrying value of noncontrolling interest totaling $3.5 million to miscellaneous, net within other income (expense) in our condensed consolidated income statement during the three-month period ended June 30, 2025.

The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs’ assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):


	As of June 30, 2025		As of December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$	9.9	$	10.0
Patient accounts receivable	8.8		8.1
Total current assets	18.7		18.1
Operating lease right of use assets	0.1		—
Goodwill	8.5		8.5
Intangible assets	0.4		0.4
Other assets	0.3		0.3
Total assets	$	28.0	$	27.3
LIABILITIES
Current liabilities:
Accounts payable	$	0.7	$	0.6
Payroll and employee benefits	1.1		1.2
Accrued expenses	9.1		9.4
Operating lease liabilities	0.1		0.1
Total liabilities	$	11.0	$	11.3

AMEDISYS INC 10-Q